Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in multiple myeloma with skeletal-related events after bisphosphonate therapy
ACTRN12624000027516Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romosozumab in multiple myeloma (MM), sponsored by St Vincent's Hospital. Primary endpoints: Safety of romosozumab in patients with multiple myeloma and Effect of romosozumab treatment on bone turnover markers. Started Jan 2024; status: recruiting.
02
Drugs
romosozumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12624000027516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000027516.